Avtal | $24,000,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026) Certified by Founder
Lodge
Ankyra Therapeutics
start up
United States
- Boston, Massachusetts
- 12/11/2021
- Series B
- $45,000,000
Developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response
- Industry Biotechnology Research
- Website https://ankyratx.com/
- LinkedIn https://www.linkedin.com/company/ankyratx/about/
Related People
Howard KaufmanFounder
United States -
Boston, Massachusetts
Experienced Chief Medical Officer with a demonstrated history of working in academic medicine and the biotechnology industry. Skilled in Cancer Research, Biotechnology, Healthcare Management, Healthcare, and Life Sciences. Strong healthcare services professional with considerable expertise in cancer immunotherapy and drug development.
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)
SetSale | $2,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)